209 related articles for article (PubMed ID: 22205272)
1. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.
Grasland A; Sterpu R; Boussoukaya S; Mahe I
Eur J Clin Pharmacol; 2012 May; 68(5):895-8. PubMed ID: 22205272
[No Abstract] [Full Text] [Related]
2. Adalimumab-induced autoimmune hepatitis.
Adar T; Mizrahi M; Pappo O; Scheiman-Elazary A; Shibolet O
J Clin Gastroenterol; 2010 Jan; 44(1):e20-2. PubMed ID: 19593165
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
Petríková J; Jarčuška P; Svajdler M; Pella D; Macejová Z
Isr Med Assoc J; 2015 Apr; 17(4):256-8. PubMed ID: 26040057
[No Abstract] [Full Text] [Related]
4. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatoid arthritis: strategies for biotherapy].
Nau JY
Rev Med Suisse; 2012 Oct; 8(358):1988-9. PubMed ID: 23198655
[No Abstract] [Full Text] [Related]
6. Biological therapy for rheumatoid arthritis: where are we now?
Horton SC; Emery P
Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404
[TBL] [Abstract][Full Text] [Related]
7. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
8. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
Titos Arcos JC; Hallal H; Robles M; Andrade RJ
Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
[No Abstract] [Full Text] [Related]
9. Biological disease modifying anti-rheumatic drugs.
Cranwell-Bruce LA
Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker.
Younis S; Rimar D; Slobodin G; Rosner I
J Rheumatol; 2012 Oct; 39(10):2055-6. PubMed ID: 23028035
[No Abstract] [Full Text] [Related]
12. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
13. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
Furst DE; Keystone EC; So AK; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Rubbert-Roth A; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop KL
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii2-34. PubMed ID: 23532441
[No Abstract] [Full Text] [Related]
14. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
15. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis.
Nardone R; Zuccoli G; Brigo F; Trinka E; Golaszewski S
Rheumatology (Oxford); 2014 Feb; 53(2):284. PubMed ID: 24191065
[No Abstract] [Full Text] [Related]
16. Abatacept.
Vital EM; Emery P
Drugs Today (Barc); 2006 Feb; 42(2):87-93. PubMed ID: 16541185
[TBL] [Abstract][Full Text] [Related]
17. Trials reveal promising options for treating juvenile rheumatoid arthritis.
Hampton T
JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
[No Abstract] [Full Text] [Related]
18. Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Perdan-Pirkmajer K; Hočevar A; Rotar Ž; Žibert J; Marolt VF; Gučev F; Tomšič M
Rheumatol Int; 2013 Nov; 33(11):2885-8. PubMed ID: 22955878
[TBL] [Abstract][Full Text] [Related]
19. Use of abatacept in rheumatoid arthritis.
von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis.
Yoshikawa N; Matsubara E; Yamamoto M; Yamazaki H; Uehara M; Kamata M; Tanaka H
Intern Med; 2020 Oct; 59(20):2611-2618. PubMed ID: 32641647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
